Understanding the mechanisms by which epigenetic modifiers avert therapy resistance in cancer
A Quagliano, A Gopalakrishnapillai, SP Barwe - Frontiers in oncology, 2020 - frontiersin.org
The development of resistance to anti-cancer therapeutics remains one of the core issues
preventing the improvement of survival rates in cancer. Therapy resistance can arise in a …
preventing the improvement of survival rates in cancer. Therapy resistance can arise in a …
Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1
Biochemical crosstalk between two or more histone modifications is often observed in
epigenetic enzyme regulation, but its functional significance in cells has been difficult to …
epigenetic enzyme regulation, but its functional significance in cells has been difficult to …
Activation of STAT and SMAD signaling induces hepcidin re-expression as a therapeutic target for β-Thalassemia patients
Iron homeostasis is regulated by hepcidin, a hepatic hormone that controls dietary iron
absorption and plasma iron concentration. Hepcidin binds to the only known iron export …
absorption and plasma iron concentration. Hepcidin binds to the only known iron export …
Gene expression profiling and protein analysis reveal suppression of the C-Myc oncogene and inhibition JAK/STAT and PI3K/AKT/mTOR signaling by thymoquinone …
Overexpression of c-Myc plays an essential role in leukemogenesis and drug resistance,
making c-Myc an attractive target for cancer therapy. However, targeting c-Myc directly is …
making c-Myc an attractive target for cancer therapy. However, targeting c-Myc directly is …
Development of a first-in-class DNMT1/HDAC inhibitor with improved therapeutic potential and potentiated antitumor immunity
Y Chang, H Guo, X Li, L Zong, J Wei, Z Li… - Journal of Medicinal …, 2024 - ACS Publications
Epigenetic therapies have emerged as a key paradigm for treating malignancies. In this
study, a series of DNMT1/HDAC dual inhibitors were obtained by fusing the key …
study, a series of DNMT1/HDAC dual inhibitors were obtained by fusing the key …
[HTML][HTML] Thymoquinone induces downregulation of BCR-ABL/JAK/STAT pathway and apoptosis in K562 leukemia cells
Objective: BCR ABL oncogene encodes the BCR-ABL chimeric protein, which is a
constitutively activated non-receptor tyrosine kinase. The BCR-ABL oncoprotein is a key …
constitutively activated non-receptor tyrosine kinase. The BCR-ABL oncoprotein is a key …
Thymoquinone Inhibits Growth of Acute Myeloid Leukemia Cells through Reversal SHP-1 and SOCS-3 Hypermethylation: In Vitro and In Silico Evaluation
Epigenetic silencing of tumor suppressor genes (TSGs) plays an essential role in cancer
pathogenesis, including acute myeloid leukemia (AML). All of SHP-1, SOCS-1, and SOCS-3 …
pathogenesis, including acute myeloid leukemia (AML). All of SHP-1, SOCS-1, and SOCS-3 …
[HTML][HTML] Thymoquinone suppresses cell proliferation and enhances apoptosis of HL60 leukemia cells through re-expression of JAK/STAT negative regulators
Objective: The natural compound, thymoquinone (TQ) has demonstrated potential
anticancer properties in inhibiting cell proliferation and promoting apoptosis in myeloid …
anticancer properties in inhibiting cell proliferation and promoting apoptosis in myeloid …
Thymoquinone inhibits JAK/STAT and PI3K/Akt/mTOR signaling pathways in MV4-11 and K562 myeloid leukemia cells
FA Al-Rawashde, AS Al-Wajeeh, MN Vishkaei… - Pharmaceuticals, 2022 - mdpi.com
Constitutive activation of Janus tyrosine kinase-signal transducer and activator of
transcription (JAK/STAT) and Phosphatidylinositol 3-kinase/Akt/mammalian target of …
transcription (JAK/STAT) and Phosphatidylinositol 3-kinase/Akt/mammalian target of …
Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure
Background Intrahepatic cholangiocarcinoma (iCCA) is a malignancy that arises from the
intrahepatic biliary tree, showing high mortality rates due to its late clinical presentation and …
intrahepatic biliary tree, showing high mortality rates due to its late clinical presentation and …